Proceeds To Fund in Part Cambium’s Upcoming FDA Dry Eye Study
ATLANTA, GA – October 6, 2017 – Cambium Medical Technologies (“Cambium”), a clinical stage company, announced today a Series A investment of $5 million from a private investor. “This funding’s timing is perfect given recent news the FDA reviewed our Phase I/II dry eye IND and gave us the green light to start our Study,” said Terence Walts, President & CEO of Cambium. “Additionally, this funding will help Cambium ramp up planned operations, key hires, and pursue new growth opportunities,” stated Walts.
About Cambium Medical Technologies LLC:
Founded in 2013 by four distinguished physician/scientists at Emory University, Atlanta, Georgia (USA)—Cambium is focused on the development of regenerative therapies through the use of novel processed human platelets. Cambium’s Mission: To improve patients’ quality of life—from within. The Company’s first FDA-approved therapy is targeted to be Elate Ocular™, a biologic eye drop for dry eye syndrome (keratoconjunctivis sicca or KCS). Elate Ocular™ utilizes Aurarix™, Cambium’s novel processed enriched platelets. Cambium’s patented human platelet lysate technology also plays a key role in UltraGRO™-Advanced and UltraGRO™ -PURE, stem cell growth supplements manufactured and sold worldwide today by Cambium’s strategic partner AventaCell Biomedical Corporation, Ltd, a subsidiary of Zheng Yang Biomedical Technology Company, Ltd, headquartered in Taipei, Taiwan.
For more information about Cambium, contact David Doolittle at +1 404-337-5990 or e-mail David at firstname.lastname@example.org, or go to www.cambiumbio.comTo learn more about AventaCell and their line of UltraGRO™ stem cell growth supplements, contact William D. Milligan at email@example.com or visit www.atcbiomed.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”) and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company’s technologies, investment in product development, possible future financings or other activities and/or statements preceded by, followed by or that include the words “believes,” “could,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “projects,” “seeks,” “potential,” “targets” or similar expressions. Investors are cautioned that all forward-looking statements involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements for any reason. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.